SPC Financial Inc. Increases Holdings in Hologic, Inc. $HOLX

SPC Financial Inc. lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,859 shares of the medical equipment provider’s stock after acquiring an additional 278 shares during the quarter. SPC Financial Inc.’s holdings in Hologic were worth $838,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Greenleaf Trust boosted its stake in shares of Hologic by 5.1% during the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock worth $233,000 after acquiring an additional 173 shares in the last quarter. Beverly Hills Private Wealth LLC boosted its stake in shares of Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock worth $320,000 after acquiring an additional 180 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 216 shares in the last quarter. First American Bank boosted its stake in shares of Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock worth $1,870,000 after acquiring an additional 245 shares in the last quarter. Finally, Integrated Advisors Network LLC boosted its stake in shares of Hologic by 5.4% during the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock worth $346,000 after acquiring an additional 289 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Stephens reissued an “overweight” rating and set a $78.00 price target on shares of Hologic in a research note on Thursday, September 18th. Morgan Stanley upped their target price on Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Mizuho set a $75.00 target price on Hologic in a research note on Thursday, July 31st. Evercore ISI set a $78.00 target price on Hologic and gave the company an “outperform” rating in a research note on Tuesday. Finally, Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $80.15.

Hologic Trading Down 1.3%

Shares of Hologic stock opened at $67.76 on Friday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The firm has a market cap of $15.07 billion, a PE ratio of 28.12, a P/E/G ratio of 2.32 and a beta of 0.63. The business’s fifty day moving average is $67.15 and its two-hundred day moving average is $63.32. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the company posted $1.06 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.88% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.